Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Reverses English Funding Rejection For Erleada After Janssen Drops Price

Executive Summary

The androgen receptor inhibitor Erleada is now considered to be a cost-effective use of National Health Service resources.

You may also be interested in...



Astellas Pips Janssen To Post With English Funding For New Prostate Cancer Indication

NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.

Alexion’s Ultomiris Wins English Funding, Janssen’s Erleada Rejected

Recommendations this week from health technology assessment body NICE relate to the treatment of two rare blood disorders with Ultomiris, and treating prostate cancer with Erleada.

New EU Filings

Vutrisiran, Alnylam’s investigational RNAi therapeutic for treating hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy, is among the latest new medicines that have been submitted for review for potential pan-EU approval.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel